Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years. * Patients with histological diagnosis of predominantly clear cell carcinoma * Availability of the tumor tissue from the primary tumor and/or a metastatic site for the genomic profiling analysis not older than 5 years. * Evaluable disease according to RECIST criteria v 1.1 * Treatment with cabozantinib after one or more previous therapies for mRCC * Patient progressed from the start to cabozantinib therapy within 3 months or after 9 months * Any prognosis group according to the IMDC risk score * Signed informed consent must be obtained for living patients. Patients who died and patient untraceable will be analyzed based on the Authorization no. 9/2016 of the Italian Data Protector Supervisor. Exclusion Criteria: * Non-availability of tumor tissue from the primary tumor or a metastatic site for biomarker analysis * Patient progressed between 3 and 9 months from the beginning of treatment with cabozantinib. * Non-availability of clinical information useful to evaluate the IMDC risk group at baseline.